Barclays
ARMP icon

Barclays’s Armata Pharmaceuticals ARMP Stock Holding History

Barclays’s Portfolio ARMP Stock Details ARMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.58K Buy
+154
New +$1.3K ﹤0.01% 4871
2025
Q4 		– Sell
-6
Closed -$18 – 5232
2025
Q3 		$18 Buy
+6
New +$16 ﹤0.01% 5364

Other funds holding ARMP

MAM
Madison Asset Management Madison, Wisconsin $8.06B AUM 11.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Barclays's ARMP Position: Q1 2026 in Review

Barclays opened a new position in Armata Pharmaceuticals (ARMP) in Q1 2026: 154 shares worth $1.58K. The stake represents ﹤0.01% of the portfolio and ranks #4871 among its holdings. This is a return to the name: Barclays previously reported a position in ARMP as recently as Q3 2025.

Barclays first reported a position in ARMP in Q3 2025 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold ARMP as of Q1 2026.

  • Barclays held 154 shares of Armata Pharmaceuticals worth $1.58K as of Q1 2026.
  • Armata Pharmaceuticals was a new Barclays position in Q1 2026.
  • Armata Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4871 holding.
  • Barclays first reported a position in Armata Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Armata Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.